Previous 10 | Next 10 |
2024-03-24 00:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 22:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26 th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 23.34% on the day to $91.79. Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or a...
Conference Call and Webcast at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will ho...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-22 17:03:07 ET More on Ligand Pharmaceuticals Johnson & Johnson posts Q4 beat as pharma and MedTech outperform FDA approves Ligand's Zelsuvmi for treatment of molluscum Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earni...
Fycompa® is the 16 th Captisol-enabled™ product approved worldwide Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour a...
2024-02-21 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-16 11:10:43 ET More on iShares Russell 2000 ETF: IWM: Technical Analysis Says You Should Buy Small Caps IWM: Supply-Side Disinflation Benefits Small Caps The Most Small-Cap ETFs: Performance, Fundamentals, And Rankings For 102 Funds Investors retract ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...